LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

Americas

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.